The morning's Q1 2019 report contained no significant surprises. The POLAR studies seem to progress according to plan, expansion studies with PledOx have been initiated, and the company is preparing the next step in the development of Aladote. We do not see any reason to change our model assumptions following the Q1 report, and we reiterate our base case fair value of SEK 52.